Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced the schedule for its second quarter 2024 financial results release. The company will disclose its financial performance after the market closes on Wednesday, August 14, 2024. Following the release, management will host a webcast and teleconference at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Investors and interested parties can participate in the teleconference by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Additionally, a live webcast presentation will be accessible via the provided weblink. For those unable to attend the live event, a replay of the webcast will be made available on the Celcuity website.
Celcuity Inc. (Nasdaq: CELC), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie oncologiche mirate, ha annunciato il calendario per il rilascio dei risultati finanziari del secondo trimestre 2024. L'azienda comunicherà le sue performance finanziarie dopo la chiusura del mercato mercoledì, 14 agosto 2024. Dopo il rilascio, la direzione ospiterà un webcast e una teleconferenza alle 16:30 ora orientale per discutere i risultati e fornire un aggiornamento aziendale.
Investitori e parti interessate possono partecipare alla teleconferenza componendo il numero 1-800-717-1738 (domestico) o 1-646-307-1865 (internazionale). Inoltre, sarà disponibile una presentazione in diretta tramite il link fornito. Per coloro che non riescono a partecipare all'evento dal vivo, sarà disponibile una registrazione del webcast sul sito web di Celcuity.
Celcuity Inc. (Nasdaq: CELC), una empresa biotecnológica en etapa clínica enfocada en desarrollar terapias oncológicas dirigidas, ha anunciado el calendario para la publicación de resultados financieros del segundo trimestre de 2024. La compañía dará a conocer su desempeño financiero después del cierre del mercado el miércoles, 14 de agosto de 2024. Después de la publicación, la dirección llevará a cabo un webcast y teleconferencia a las 4:30 p.m. hora del este para discutir los resultados y proporcionar una actualización corporativa.
Los inversores y partes interesadas pueden participar en la teleconferencia marcando el 1-800-717-1738 (nacional) o 1-646-307-1865 (internacional). Además, se podrá acceder a una presentación en vivo a través del enlace proporcionado. Para aquellos que no puedan asistir al evento en vivo, se realizará una repetición del webcast en el sitio web de Celcuity.
Celcuity Inc. (Nasdaq: CELC)는 목표 항암 치료제를 개발하는 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과 발표 일정을 발표했습니다. 회사는 2024년 8월 14일 수요일 시장이 마감된 후 재무 성과를 공개할 예정입니다. 발표 후 경영진은 동부 표준시 기준 오후 4시 30분에 결과를 논의하고 기업 업데이트를 제공하는 웨비나 및 전화 회의를 주최할 것입니다.
투자자 및 이해관계자는 1-800-717-1738(국내) 또는 1-646-307-1865(국제)로 전화 회의에 참여할 수 있습니다. 또한 제공된 웹 링크를 통해 실시간 웨비나 발표에 액세스할 수 있습니다. 실시간 이벤트에 참석할 수 없는 경우, Celcuity 웹사이트에서 웨비나의 재생본을 이용할 수 있습니다.
Celcuity Inc. (Nasdaq: CELC), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies oncologiques ciblées, a annoncé le calendrier de la publication de ses résultats financiers du deuxième trimestre 2024. La société divulguera sa performance financière après la fermeture du marché le mercredi 14 août 2024. Suite à la publication, la direction animera un webinaire et une téléconférence à 16h30 heure de l'Est pour discuter des résultats et fournir une mise à jour de l'entreprise.
Les investisseurs et les parties intéressées peuvent participer à la téléconférence en composant le 1-800-717-1738 (national) ou le 1-646-307-1865 (international). De plus, une présentation en direct sera accessible via le lien fourni. Pour ceux qui ne peuvent pas assister à l'événement en direct, un enregistrement du webinaire sera disponible sur le site Web de Celcuity.
Celcuity Inc. (Nasdaq: CELC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung zielgerichteter Onkologie-Therapien konzentriert, hat den Zeitplan für die Veröffentlichung der Finanzergebnisse des zweiten Quartals 2024 bekannt gegeben. Das Unternehmen wird seine finanzielle Leistung nach Marktabschluss am Mittwoch, den 14. August 2024 bekannt geben. Nach der Veröffentlichung wird das Management um 16:30 Uhr Eastern Time eine Webcast- und Telefonkonferenz abhalten, um die Ergebnisse zu erörtern und ein Unternehmensupdate zu geben.
Investoren und interessierte Parteien können an der Telefonkonferenz teilnehmen, indem sie 1-800-717-1738 (inländisch) oder 1-646-307-1865 (international) wählen. Darüber hinaus ist eine Live-Webcast-Präsentation über den bereitgestellten Link zugänglich. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine Wiederholung des Webcasts auf der Celcuity-Website verfügbar sein.
- None.
- None.
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1678191&tp_key=c55c86e8c3. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Westwicke
Maria Yonkoski, maria.yonkoski@westwicke.com
(203) 682-7167
FAQ
When will Celcuity (CELC) release its Q2 2024 financial results?
How can investors participate in Celcuity's (CELC) Q2 2024 earnings call?
What time is Celcuity's (CELC) Q2 2024 earnings webcast and conference call?
Will there be a replay available for Celcuity's (CELC) Q2 2024 earnings webcast?
